Search Results - dan+li

3 Results

Sort By:

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Summary: The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies. Description of Technology: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li

Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Abstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National...

Published: 5/14/2025 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Nan Li, Dan Li

Keywords(s): CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors

Description of Technology: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape. PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Glenn Merlino, Dan Li, Hejiao English, Chi-Ping Day

Keywords(s): adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology